(Q38644070)

English

Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Yoojin Noh

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Dae Ryong Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Dae Jung Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Kwang Jae Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sukhyang Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sooyoung Shin

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Pharmacoepidemiology and Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1338-1346

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Use of antidiabetic drugs in the U.S., 2003-2012.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Systematic reviews to ascertain the safety of diabetes medications

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Thiazolidinedione safety

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.4262

21 January 2018

Identifiers

10.1002/PDS.4262

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28771933%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38644070&oldid=1512245782"